Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Develops and commercializes therapeutics for patients in Greater China with cardiovascular and ophthalmic diseases.
Jixing Pharmaceuticals is a Shanghai, China-based company that partners with global biotechnology firms to develop and commercialize innovative therapeutics for unmet medical needs in cardiovascular and ophthalmic diseases. The company primarily focuses on bringing novel medicines to underserved patients in Greater China with serious and life-threatening conditions, maintaining a strong asset pipeline. Jixing has secured substantial venture investments, including $287 million in Series D funding, and is backed by prominent investors such as RTW Investments and Bayer. It has established partnerships with companies like Cytokinetics and Vincentage, notably selling rights to Cytokinetics’ aficamten to Sanofi in 2024. Operating from a 25,833 sqft office, the organization was founded in 2019. Its business model centers on funded through venture investments including Series B, C, and D rounds from RTW Investments and others, generates value by licensing and commercializing partnered therapeutics in China.
Jixing Pharmaceuticals has raised $609.0M across 3 funding rounds.
Jixing Pharmaceuticals has raised $609.0M in total across 3 funding rounds.
Jixing Pharmaceuticals has raised $609.0M across 3 funding rounds. Most recently, it raised $287.0M Series D in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 26, 2026 | $287M Series D | — | Adage Capital Management, HBM Healthcare Investments, Hengdian Group Capital, Invus, RA Capital Management, Roderick Wong, Silver ARC Private Capital, SR ONE, SymBiosis, TCGX | Announced |
| Jan 15, 2024 | $162M Venture Round | Juergen Eckhardt, Peter Fong | — | Announced |
| Jan 1, 2024 | $160M Series D | — | Anthony Philippakis, RTW Investments | Announced |
Jixing Pharmaceuticals has raised $609.0M in total across 3 funding rounds.
Jixing Pharmaceuticals's investors include Adage Capital Management, HBM Healthcare Investments, Hengdian Group Capital, Invus, RA Capital Management, Roderick Wong, Silver Arc Private Capital, SR One, SymBiosis, TCGX, Juergen Eckhardt, Peter Fong.
Ji Xing Pharmaceuticals is a biopharmaceutical company founded in 2019 and headquartered in Shanghai, China, specializing in novel therapeutics for cardiovascular and ophthalmic diseases.[1][2][3] It develops treatments for conditions like hypertrophic cardiomyopathy, heart failure, paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation, hypertension, dry eye disease, and presbyopia, primarily serving patients and the healthcare industry in these areas.[1] Key pipeline assets include etripamil (a nasal spray calcium channel blocker licensed from Milestone Pharmaceuticals in 2021 for PSVT and AFib-RVR), JX09 and JX10 (investigational drugs for hypertension and acute ischemic stroke via its CORXEL initiative), and BIIB131 (acquired from Biogen in 2024).[1][2][3] The company has shown growth through strategic partnerships, such as with Bayer and investments from RTW Investments, positioning it to address unmet needs in cardiometabolic disorders with a global clinical network spanning the US and China.[2][3]
Ji Xing Pharmaceuticals was established in 2019 in Jing'An, Shanghai, China, at 1225 West Nanjing Road.[1][2] Limited public details exist on specific founders, but the leadership includes CEO Joseph Romanelli and board member Zhou Xiaolan, reflecting a team with expertise in medical, clinical, CMC, regulatory, and business development across the US and China.[2][3] The company emerged to tackle urgent patient needs in cardiovascular and ophthalmic fields, quickly advancing through licensing deals like etripamil from Milestone Pharmaceuticals in May 2021 and acquisitions such as BIIB131 from Biogen in May 2024.[1][3] Early momentum built via global networks for efficient clinical trials and partnerships, including collaborations with Bayer announced in early 2024.[3]
Ji Xing rides the wave of China's booming biotech sector, where demand for innovative cardiometabolic and ophthalmic therapies surges amid aging populations and rising chronic disease prevalence.[1][4] Timing aligns with global shifts toward self-administered therapies and efficient clinical networks, amplified by post-pandemic emphasis on accessible treatments like nasal sprays over invasive procedures.[1] Market forces favoring it include substantial private investments (e.g., January 2024 rounds) and partnerships with multinationals like Bayer and Biogen, which provide capital and expertise to bridge China-US regulatory gaps.[3] It influences the ecosystem by accelerating trials for underserved indications, fostering cross-border innovation, and exemplifying how China-based biotechs localize global assets to serve domestic needs.[2][4]
Ji Xing is poised for pipeline milestones, including potential NDA progress for etripamil (building on Milestone's Phase III/FDA submissions) and Phase advancements for JX09/JX10/BIIB131, supported by its global network.[1][2] Trends like AI-driven trials, expanded self-care devices, and China’s healthcare reforms will shape its path, potentially driving commercialization in Greater China by 2026-2028. Its influence may grow through more in-licenses and IPO pursuits, solidifying its role as a cardiovascular biotech leader—transforming patient access from reactive hospital care to proactive, at-home solutions.[3][4]